Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nafoxidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.98 |
| ▸ | ESR1 known ✓ | P03372 | 14/20 | 0.60 |
| ▸ | ESR2 known ✓ | Q92731 | 10/20 | 0.60 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | EBP | Q15125 | 1/20 | 0.98 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafoxidine SCHEMBL29562423 | 1.00 | EBP (0.98) | EBPSIGMAR1ESR1ESR2LTA4H | |
| Nafoxidine SCHEMBL8430193 | 1.00 | EBP (0.98) | EBPSIGMAR1ESR1ESR2LTA4H | |
| Nafoxidine SCHEMBL153125 | 0.99 | EBP (1.00) | EBPSIGMAR1ESR1ESR2LTA4H | |
| Nafoxidine SCHEMBL10563464 | 0.99 | EBP (1.00) | EBPSIGMAR1ESR1ESR2LTA4H | |
| Nafoxidine SCHEMBL29494604 | 0.99 | EBP (1.00) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL8015672 | 0.93 | EBP (0.88) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL2811903 | 0.93 | EBP (0.88) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL13350303 | 0.92 | EBP (0.86) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL2811811 | 0.92 | EBP (0.86) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL2817373 | 0.92 | EBP (0.86) | EBPSIGMAR1ESR1ESR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937188-B2 | Process for the preparation of lasofoxifene tartrate | GLENMARK GENERICS LTD. (IN) | 2015-01-20 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-2424839-A2 | A PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | Glenmark Generics Limited (IN) | 2012-03-07 | — | — | EP | claimed |
| US-20120045648-A1 | PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | GLENMARK GENERRICS LTD (IN) | 2012-02-23 | — | — | US | claimed |
| WO-2010125578-A2 | A PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | GLENMARK GENERICS LIMITED (IN) | 2010-11-04 | — | — | WO | claimed |
| EP-1899310-B1 | STEREOSELECTIVE HYDROGENATION PROCESS FOR PREPARING CIS-6-PHENYL-5-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-2-METHOXY-5,6,7,8-TETRAHYDRONAPHTHALENE HYDROCHLORIDE | PFIZER PROD INC (US) | 2010-09-29 | — | — | EP | claimed |
| US-20100160648-A1 | STEREOSELECTIVE HYDROGENATION PROCESS FOR PREPARING CIS-6-PHENYL-5-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-2-METHOXY-5,6,7,8-TETRAHYDRONAPHTHALENE HYDROCHLORIDE | TABER GERALDINE PATRICIA | 2010-06-24 | — | — | US | claimed |
| EP-1899310-A1 | STEREOSELECTIVE HYDROGENATION PROCESS FOR PREPARING CIS-6-PHENYL-5-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-2-METHOXY-5,6,7,8-TETRAHYDRONAPHTHALENE HYDROCHLORIDE | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | claimed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | claimed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | claimed |
| US-6362237-B1 | MIXTURE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-03-26 | — | — | US | claimed |
| EP-0799042-A1 | COMPOUNDS WITH PROGESTERONE-ANTAGONISTIC AND ANTI-OESTROGEN PROPERTIES INTENDED FOR COMBINED USE IN FEMALE CONTRACEPTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019997-A1 | COMPOUNDS WITH PROGESTERONE-ANTAGONISTIC AND ANTI-OESTROGEN PROPERTIES INTENDED FOR COMBINED USE IN FEMALE CONTRACEPTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-07-04 | — | — | WO | claimed |
| US-4859695-A | Antiestrogen agents having anabolic activity in animals | MERCK & CO., INC. (US) | 1989-08-22 | — | — | US | claimed |
| US-4657349-A | INFORMATION DISPLAY | TEMPLE UNIVERSITY (US) | 1987-04-14 | — | — | US | claimed |
| EP-0171958-A1 | Electro- and magneto-optic devices | Temple University of the Commonwealth System of Higher Education (US) | 1986-02-19 | — | — | EP | claimed |
| US-4310523-A | Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160648-A1 | STEREOSELECTIVE HYDROGENATION PROCESS FOR PREPARING CIS-6-PHENYL-5-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-2-METHOXY-5,6,7,8-TETRAHYDRONAPHTHALENE HYDROCHLORIDE | PAH, P4HA1, HPD | SIGMAR1 1564/4885ESR1 1035/4885ESR2 455/4885 |
| US-20120045648-A1 | PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | CYP19A1, CYP51A1, CYP2F1 | SIGMAR1 1272/4885ESR1 25/4885ESR2 40/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | SIGMAR1 3299/4885ESR1 1012/4885ESR2 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.